DUBLIN–(BUSINESS WIRE)–The “Grass Pollen Allergy (Immunology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.
Grass Pollen Allergy – Drugs In Development, 2021, provides an overview of the Grass Pollen Allergy (Immunology) pipeline landscape.
Grass Pollen Allergy – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Grass Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Grass Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 6 and 1 respectively.
Grass Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Grass Pollen Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Grass Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
Grass Pollen Allergy – Overview
- Grass Pollen Allergy – Therapeutics Development
Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
Grass Pollen Allergy – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Grass Pollen Allergy – Companies Involved in Therapeutics Development
- ALK-Abello AS
- Allergy Therapeutics Plc
- ASIT Biotech SA
- DC4U BV
- HAL Allergy BV
- Regeneron Pharmaceuticals Inc
- Roxall Medizin GmbH
- Worg Pharmaceuticals Hangzhou Co Ltd
Grass Pollen Allergy – Drug Profiles
- Allergen for Grass Pollen Allergy – Drug Profile
- Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile
- dupilumab – Drug Profile
- gp-ASIT – Drug Profile
- Pollinex Quattro Grass – Drug Profile
- standardized grass pollen [timothy (Phleum pratense)] allergen extract – Drug Profile
- Vaccine for Grass Pollen Allergy – Drug Profile
- Vaccine for Grass Pollen Allergy and House Dust Mite Allergy – Drug Profile
- WP-1048 – Drug Profile
Grass Pollen Allergy – Dormant Projects
Grass Pollen Allergy – Discontinued Products
Grass Pollen Allergy – Product Development Milestones
Featured News & Press Releases
- May 06, 2021: Allergy Therapeutics: Completion of treatment phase in G309 study
- Aug 26, 2020: Chronic hepatitis B: vaccine against grass pollen allergy as potential treatment
- Nov 26, 2019: Allergy Therapeutics announces update to Grass MATA MPL phase III clinical programme
- Jun 27, 2019: Allergy Therapeutics: Successful litigation settlement relating to PQ Grass Phase II Trial
- Apr 25, 2019: Allergy Therapeutics provides regulatory and trading update
- Jun 25, 2018: Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy
- May 21, 2018: Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study
- Feb 05, 2018: Landmark clinical study with grass pollen vaccine BM32 published
- Jan 26, 2017: Biomay AG Reports Positive Results From A Second Phase IIb Trial With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32
- Sep 08, 2016: Grass pollen allergy vaccine also effective against hepatitis B
- Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204
- Jun 13, 2016: New Data From GAP Landmark Trial Confirm GRAZAX Prevents Asthma Symptoms in Children
- Mar 04, 2016: Inflamax Research Announces the Successful Completion of Enrollment for the First Multi-center, Mobile Environmental Exposure Chamber (mEEC) Study
- Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL
- Jan 28, 2016: Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32
Appendix
For more information about this report visit https://www.researchandmarkets.com/r/76hmfc
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900